CELGENE

Celgene Corporation, the biopharmaceutical company, said Wednesday that it would buy Abraxis BioScience in a cash and stock deal that values the company at $2.9 billion.
Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58.00 in cash and 0.2617 shares of Celgene common stock. ...
NEW YORK (AP) — Biotechnology company Celgene said Wednesday it is expanding its array of cancer treatments with a deal to buy Abraxis BioScience Inc. for.

Celgene in WIKIPEDIA